The Hepatology Program at Michigan Medicine is one of the largest and most well-established programs in the country. We specialize in the diagnosis and management of acute liver failure, hepatitis B and C, autoimmune liver disease, primary biliary cirrhosis, primary sclerosing cholangitis, alcoholic liver disease, non-alcoholic fatty liver disease, Wilson disease, cirrhosis of any cause, hepatocellular carcinoma (liver cancer), livertransplantation, and complications of portal hypertension.
Our mission is to provide state-of-the-art, innovative, and compassionate care to patients affected by liver diseases through the General Hepatology, Alcoholic Liver Disease, Nonalcoholic Fatty Liver Disease, Wilson Disease, Liver Tumor, and Liver Transplantation Clinics. As part of this mission, we provide multidisciplinary care so patients can be evaluated by physicians from all appropriate disciplines during a single visit. In addition, we are actively engaged in clinical and translational research including novel therapies, improved diagnostic modalities, and better biomarkers and predictors of outcome. All patients seen in any of our Hepatology Clinics who are potential candidates for new therapies and other research protocols are referred for participation in clinical trials.
Headed by Anna Lok, MD, FRCP, past president of American Association for the Study of Liver Diseases, the Hepatology Program includes sixteen faculty members with expertise in a wide variety of liver diseases. Our faculty play key roles in multiple NIH-sponsored clinical research networks, including acute liver failure, biomarkers for early diagnosis of hepatocellular carcinoma, drug-induced liver injury, and hepatitis B.
We are also involved in many clinical trials supported by pharmaceutical companies. These trials evaluate new therapies for various liver diseases including hepatitis B and C, fatty liver, and hepatocellular carcinoma.
Follow us on Twitter @MichiganLiver for the latest Michigan Hepatology news.